ES2179096T3 - Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped. - Google Patents

Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.

Info

Publication number
ES2179096T3
ES2179096T3 ES95908628T ES95908628T ES2179096T3 ES 2179096 T3 ES2179096 T3 ES 2179096T3 ES 95908628 T ES95908628 T ES 95908628T ES 95908628 T ES95908628 T ES 95908628T ES 2179096 T3 ES2179096 T3 ES 2179096T3
Authority
ES
Spain
Prior art keywords
interleucine
guest
prevent reaction
graft against
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95908628T
Other languages
English (en)
Inventor
Stanley F Wolf
Megan Sykes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Genetics Institute LLC
Original Assignee
General Hospital Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Genetics Institute LLC filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2179096T3 publication Critical patent/ES2179096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA EL USO DE LA INTERLEUQUINA-12 PARA PREVENIR, MEJORAR Y TRATAR INJERTOS CONTRA ENFERMEDADES DEL ANFITRION EN UN MAMIFERO EN NECESIDAD DE DICHO TRATAMIENTO.
ES95908628T 1994-01-21 1995-01-20 Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped. Expired - Lifetime ES2179096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ES2179096T3 true ES2179096T3 (es) 2003-01-16

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95908628T Expired - Lifetime ES2179096T3 (es) 1994-01-21 1995-01-20 Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.

Country Status (14)

Country Link
US (2) US5573764A (es)
EP (1) EP0739212B1 (es)
JP (1) JP3825043B2 (es)
AT (1) ATE215380T1 (es)
AU (1) AU698410B2 (es)
CA (1) CA2181568C (es)
DE (1) DE69526206T2 (es)
DK (1) DK0739212T3 (es)
ES (1) ES2179096T3 (es)
IL (1) IL112373A (es)
PT (1) PT739212E (es)
TW (1) TW349021B (es)
WO (1) WO1995019786A1 (es)
ZA (1) ZA95463B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
WO1997016203A1 (en) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Methods for administration of il-12
EP0956301A2 (en) * 1996-10-18 1999-11-17 Valentis Inc. Il-12 gene expression and delivery systems and uses
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
WO1998051327A1 (en) * 1997-05-16 1998-11-19 Toray Industries, Inc. Therapeutic agent, treatment method, prophylactic agent, and prophylactic method for canine and feline immunological diseases
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
WO2003020904A2 (en) * 2001-08-31 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of generating human cd4+ th1 cells
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
WO2003038062A2 (en) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
BRPI0818287A2 (pt) * 2007-10-08 2015-11-03 Intrexon Corp células dendríticas manipuladas e usos para o tratamento do câncer.
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
US9878012B2 (en) 2010-05-18 2018-01-30 Neumedicines, Inc. IL-12 formulations for enhancing hematopoiesis
WO2012174056A1 (en) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
CA2843014C (en) 2011-07-27 2020-01-21 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2766035B1 (en) * 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
JP2015505326A (ja) 2012-01-18 2015-02-19 ニューメディシンズ,インコーポレーテッド 放射線防護及び放射線誘発性毒性緩和のためのil−12
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
CN115916261A (zh) * 2020-04-17 2023-04-04 小利兰·斯坦福大学董事会 工程化il-12和il-23多肽及其用途
US12071633B2 (en) * 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
US20240041939A1 (en) * 2021-12-17 2024-02-08 William Marsh Rice University Encapsulated cells expressing il-12 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
ATE215380T1 (de) 2002-04-15
EP0739212A1 (en) 1996-10-30
WO1995019786A1 (en) 1995-07-27
US5756085A (en) 1998-05-26
CA2181568C (en) 2007-09-18
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
US5573764A (en) 1996-11-12
JPH09508371A (ja) 1997-08-26
AU698410B2 (en) 1998-10-29
IL112373A0 (en) 1995-03-30
DE69526206D1 (de) 2002-05-08
PT739212E (pt) 2002-08-30
JP3825043B2 (ja) 2006-09-20
IL112373A (en) 2006-08-01
TW349021B (en) 1999-01-01
EP0739212B1 (en) 2002-04-03
CA2181568A1 (en) 1995-07-27
AU1687595A (en) 1995-08-08
ZA95463B (en) 1995-09-27

Similar Documents

Publication Publication Date Title
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
SE9702860D0 (sv) New use
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
PT703786E (pt) Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
GB9425730D0 (en) Compounds
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
IL131478A0 (en) Methods for treatment of scar tissue
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
GB9626472D0 (en) New use of comt inhibitors
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
MX9206135A (es) Metodos
RU94039553A (ru) Средство для лечения хронического простатита